Adocia SA

Paris Stock Exchange:ADOC.PA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

🐶 Pet Food

💊 Pharmaceuticals

Location

France

Market Cap

USD 81.54 M

Share Price

USD 4.34

Avg Daily Volume

165,344

Change (1 day)

0.51%

Change (1 year)

-46.17%

Change (YTD)

-30.21%

Adocia SA Revenue for the year ending December 31, 2024

Adocia SA Revenue is NA for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Adocia SA Revenue for the year ending December 31, 2023 was USD 2.37 M, a -80.62% change year over year.
Adocia SA Revenue for the year ending December 31, 2022 was USD 12.25 M, a 645.09% change year over year.
Adocia SA Revenue for the year ending December 31, 2021 was USD 1.64 M, a 60.00% change year over year.
Adocia SA Revenue for the year ending December 31, 2020 was USD 1.03 M, a -57.28% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Paris Stock Exchange: ADOC.PA

Adocia SA

CEO	Mr. Olivier Soula M.B.A., Ph.D.
IPO Date	Feb. 20, 2012
Location	France
Headquarters	115 Avenue Lacassagne
Employees	76
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🔬 Chemicals & Advanced Materials 🐶 Pet Food 💊 Pharmaceuticals

Description

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.